US$ 25.70
glp-1 receptor agonist type 1 diabetes trial liraglutide It's important to study the difference in medications. Our analysis found tirzepatide is associated with a lower risk of serious heart and kidney complications compared to dulaglutide in adults with Liraglutide, a glucagon-like peptide-1 analog,
Description
It is manufactured by Sun Pharma in India and approved by DCGI after a Phase III trial conducted in India
(2020, March)

Ravi Rao January 2, 2026 JAMA Surgery has published a new research which demonstrates that bariatric surgery continues to serve as an effective treatment for severe obesity as it produces better results than GLP 1 weight-loss medications

Short-acting drugs primarily lower postprandial blood glucose levels by slowing gastric emptying, while long-acting GLP-1 RAs are more effective at reducing fasting blood glucose levels, mainly by promoting insulin secretion and inhibiting glucagon release
A GLP-1 Receptor Agonist Liraglutide Inhibits Endothelial Cell Dysfunction and Vascular Adhesion Molecule Expression in an ApoE-/- Mouse Model